In a preclinical model of HNSCC, ABT-806 reduced the growth of xenograft tumors expressing both EGFRvIII and wild-type EGFR, suggesting that it may provide a therapeutic option for HNSCC with EGFRvIII [94]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.